Aurilio G.; Cimadamore A.; Lopez-Beltran A.; Scarpelli M.; Massari F.; Verri E.; Cheng L.; Santoni M.; Montironi R., Narrative review: Update on immunotherapy and pathological features in patients with bladder cancer, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1521 - 1529 [Scientific article]Open Access
de Velasco G.; Ruiz-Granados A.; Reig O.; Massari F.; Climent Duran M.A.; Verzoni E.; Graham J.; Llarena R.; De Tursi M.; Donskov F.; Iglesias C.; Pandha H.S.; Garcia del Muro X.; Procopio G.; Oudard S.; Castellano D.; Albiges L., Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib, «BJU INTERNATIONAL», 2021, 128, pp. 254 - 261 [Scientific article]
Rizzo A.; Santoni M.; Mollica V.; Logullo F.; Rosellini M.; Marchetti A.; Faloppi L.; Battelli N.; Massari F., Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2021, 17, pp. 1455 - 1466 [Scientific article]
Mollica, Veronica; Rizzo, Alessandro; Tassinari, Elisa; Giunchi, Francesca; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study, «ANTI-CANCER DRUGS», 2021, 32, pp. 74 - 81 [Scientific article]
Basso U.; Facchinetti A.; Rossi E.; Maruzzo M.; Conteduca V.; Aieta M.; Massari F.; Fraccon A.P.; Mucciarini C.; Sava T.; Santoni M.; Pegoraro C.; Durante E.; Nicodemo M.; Perin A.; Bearz A.; Gatti C.; Fiduccia P.; Diminutto A.; Barile C.; De Giorgi U.; Zamarchi R.; Zagonel V., Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial, «THE ONCOLOGIST», 2021, 26, pp. 740 - 750 [Scientific article]
Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Massari F.; Santoni M.; Scarpelli M.; Cheng L.; Montironi R., Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation, «CANCERS», 2021, 13, Article number: 3471 , pp. 1 - 12 [Scientific article]Open Access
Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F., Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review, «FUTURE ONCOLOGY», 2021, 17, pp. 2671 - 2681 [Scientific article]
Rizzo A.; Mollica V.; Massari F., Randomized Clinical Trials in the Era of Precision Oncology - The Role of End Points, Industry Funding, and Medical Writing Integrity, «JAMA ONCOLOGY», 2021, 7, pp. 1577 - 1577 [Scientific article]
Cimadamore A.; Cheng L.; Scarpelli M.; Lopez-Beltran A.; Mollica V.; Montironi R.; Massari F., Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation, «EUROPEAN UROLOGY», 2021, 79, pp. 17 - 19 [Scientific article]
Santoni M.; Massari F.; Santoni G.; Cimadamore A.; Montironi R.; Battelli N., Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy, «EUROPEAN UROLOGY», 2021, 79, pp. 887 - 889 [Scientific article]
Rizzo A.; Mollica V.; Massari F., Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35, «EUROPEAN UROLOGY ONCOLOGY», 2021, 4, pp. 670 - 670 [Scientific article]
Mollica V.; Rizzo A.; Massari F., Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?, «EUROPEAN UROLOGY ONCOLOGY», 2021, 4, pp. 854 - 854 [Scientific article]
Franceschini, Tania; Giunchi, Francesca; Mollica, Veronica; Altimari, Annalisa; Capizzi, Elisa; Banfi, Mattia; Schiavina, Riccardo; Fiorentino, Michelangelo; Massari, Francesco, Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study, «DIAGNOSTICS», 2021, 11, Article number: 184 , pp. 1 - 6 [Scientific article]Open Access
Rizzo A.; Merler S.; Sorgentoni G.; Oderda M.; Mollica V.; Gadaleta-Caldarola G.; Santoni M.; Massari F., Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2021, 17, pp. 1237 - 1243 [Scientific article]
Rizzo A.; Mollica V.; Santoni M.; Massari F., Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 1225 - 1232 [Scientific article]
